Viridian Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Viridian Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Viridian Therapeutics Inc Strategy Report
- Understand Viridian Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Viridian Therapeutics Inc (Viridian), formerly Miragen Therapeutics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. It focuses on thyroid eye disease and cardiovascular disease areas. It’s lead pipeline products candidates include VRDN-001 (Intravenous) for treating thyroid eye disease (TED); and VRDN-002 (Subcutaneous), an inhibitor using half-life technology for treating thyroid eye disease (TED). The company has been depending on the third parties for the manufacturing and supply of the products. Viridian is headquartered in Boulder, Colorado, the US.
Headquarters
United States of America
Address
221 Crescent Street, Bldg. 17, Suite 401, Waltham, Massachusetts, 02453
Website
www.viridiantherapeutics.com
Telephone
1 617 2724600
No of Employees
96
Industry
Medical Equipment
Ticker Symbol & Exchange
VRDN (NASD)
Revenue (2022)
$314,000
-82.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-83%
(2022 vs 2021)
Market Cap*
$797.2M
Net Profit Margin (2022)
XYZ
-933.0%
(2022 vs 2021)
* As of and is in US$
Viridian Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| VRDN-002 - thyroid eye disease (TED) - Subcutaneous |
| VRDN-001 - thyroid eye disease (TED) - Intravenous |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company announced a partnership with Enable Injections to utilize the enFuse technology. |
| 2022 | New Product Approvals | In January, the company announced the FDA clearence for Investigational New Drug Application for VRDN-002. |
| 2022 | New Product Approvals | In January, the company submitted Investigational New Drug Application for VRDN-002 to US FDA. |
Competitor Comparison
| Key Parameters | Viridian Therapeutics Inc | Horizon Therapeutics Plc | Ionis Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | Dicerna Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Waltham | Dublin | Carlsbad | Pasadena | Lexington |
| State/Province | Massachusetts | - | California | California | Massachusetts |
| No. of Employees | 96 | 2,190 | 927 | 525 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Scott Myers | Director; President; Chief Executive Officer | Executive Board | 2023 | 57 |
| Stephen Mahoney | President; Chief Executive Officer | Executive Board | 2023 | - |
| Jennifer Tousignant | Chief Legal Officer | Senior Management | 2024 | - |
| Janielle Newland | Chief Administrative Officer | Senior Management | 2021 | - |
| Thomas Ciulla | Chief Medical Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer